Hester Biosciences Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

The company?s currently holds around 54.81% stake in Texas Lifesciences.

Texas Lifesciences had recorded a turnover of Rs 28.59 crore and its net worth was Rs 13.41 crore in FY2024-25.

Offering details of this transaction, the company stated that the 43.81% shareholding of Hester will be transferred to Ticop Life, an entity affiliated to the existing promoter shareholders of TLPL.

Hester will continue to do business with TLPL and maintain an 11% equity stake in the company.

The company expects to conclude this transaction within a period of three months from the date of this agreement. It will receive a consideration of Rs 9.2 crore as a part of this transaction.

Hester Biosciences Limited is one of the India?s leading animal health company, manufacturing vaccines and health products. It is the second largest poultry vaccine manufacturer, with approximately 35% market share in India.

The company had reported 24.79% fall in consolidated net profit to Rs 8.77 crore despite a 22.46% increase in revenue to Rs 77.42 crore in Q3 FY26 as compared with Q3 FY25.

The scrip fell 0.17% to currently trade at Rs 1450.00 on the BSE.

Powered by Capital Market - Live News

The board of Hester Biosciences at its meeting held on 11 March 2026 has approved the divestment of 43.81% equity stake out of total 54.81% in its subsidiary, Texas Lifesciences (TLPL), by way of transfer/sale of shares to the existing promoter shareholders of the TLPL for a consideration of Rs 9.2 crore.

TLPL is not material subsidiary of the Company. TLPL will ceased to be the subsidiary of the Company upon completion share transfer transaction as above.

Hester will continue to do business with TLPL and maintain an 11% equity stake/investment in the company.

Powered by Capital Market - Live News

Net profit of Hester Biosciences declined 24.79% to Rs 8.77 crore in the quarter ended December 2025 as against Rs 11.66 crore during the previous quarter ended December 2024. Sales rose 22.46% to Rs 77.42 crore in the quarter ended December 2025 as against Rs 63.22 crore during the previous quarter ended December 2024.

Powered by Capital Market - Live News

Hester Biosciences will hold a meeting of the Board of Directors of the Company on 30 January 2026.

Powered by Capital Market - Live News